Is there one standard price for semaglutide?

No. Semaglutide is sold as Wegovy (weight), Ozempic (diabetes), and Rybelsus (oral, diabetes), and what you pay depends on the brand, your diagnosis, and your payment pathway: list price, insured copay, manufacturer savings card, cash self-pay, or a non-FDA-approved compounded version. Each produces a different number for the same molecule.

Why is Wegovy sometimes not covered when Ozempic is?

Insurers treat a weight-loss drug differently from a diabetes drug even when the ingredient is identical. Wegovy is FDA-approved for chronic weight management, and many plans either require prior authorization tied to BMI criteria or exclude weight-loss medications entirely. Ozempic is approved for type 2 diabetes, which some plans cover more readily. Where to confirm: your plan formulary and NovoCare.

Do the Novo Nordisk savings cards work with Medicare or Medicaid?

Generally no. Manufacturer savings programs for Wegovy and Ozempic are typically limited to commercially insured or eligible cash-paying patients and exclude prescriptions paid by government programs such as Medicare, Medicaid, or TRICARE. Check the current terms on Novo Nordisk's Save on Wegovy and Save on Ozempic pages.

Is compounded semaglutide a safe way to pay less?

Compounded semaglutide is often cheaper but is not an FDA-approved product, and the FDA has warned about unapproved and compounded GLP-1 products. It has not gone through the review that verifies identity, strength, quality, and purity. A lower price does not remove that risk, so discuss it with a licensed prescriber before choosing this route.

Where can I find the actual current price?

On the manufacturer's own pages. Novo Nordisk publishes cost, coverage, and savings information for Wegovy and Ozempic through its NovoCare and savings pages. These figures change, so treat any price quoted elsewhere as approximate and confirm it at the source.

Can I use Ozempic for weight loss to save money?

Using Ozempic for weight alone is off-label, since Ozempic is FDA-approved for type 2 diabetes, not weight management. Insurers may decline coverage when the documented reason is weight, which can push you to a cash pathway anyway. The FDA-approved weight product is Wegovy, and pricing it across its own pathways is usually the cleaner comparison.

GLP-1 · Cost

How Much Does Semaglutide Cost? A Real Breakdown by Brand, Insurance, and Savings Path

Educational guide · By ClearHormones Editorial Team · Updated July 2026

There is no single price for semaglutide, and that is the honest answer to the question. What you pay depends less on the molecule itself and more on which branded product you are prescribed, what condition it is treating, and how you are paying. The same active ingredient sits inside Wegovy (approved for chronic weight management), Ozempic (approved for type 2 diabetes), and Rybelsus (the oral tablet form for type 2 diabetes) — and each carries its own list price, insurance treatment, and savings program.

Key takeaways

Semaglutide has no single price. The same molecule is sold as Wegovy (weight), Ozempic (diabetes), and Rybelsus (oral, diabetes), each with its own list price and coverage rules.
Your out-of-pocket cost is set by your pathway, not the drug: list price, insured copay, manufacturer savings card, cash self-pay, or a non-FDA-approved compounded version.
Manufacturer savings cards from Novo Nordisk can sharply lower cost for eligible commercially insured patients but generally exclude Medicare, Medicaid, and other government coverage.
Insurance frequently covers Wegovy for weight only when you meet the FDA BMI criteria on the label, and often requires prior authorization; many plans exclude weight-loss drugs entirely.
Compounded semaglutide is usually cheaper but is not an FDA-approved product; the FDA has warned about unapproved and compounded GLP-1 products.
The live, accurate price is on the manufacturer's own savings and NovoCare coverage pages, because these figures change over time.

The short answer

Because of that, the useful way to think about semaglutide cost is not "what is the price" but "which cost pathway am I on." There are five: the manufacturer's list price, an insured copay, a manufacturer savings card, a cash self-pay rate through the maker's own pharmacy, and a compounded version made by a pharmacy that is not FDA-approved. Each pathway produces a wildly different out-of-pocket number for the identical drug, and moving from one to another is usually where real money is saved or lost.

This page maps those five pathways, explains which one you likely qualify for, and points you to the manufacturer's own coverage pages — the only place a current, accurate dollar figure lives, since these prices change. It also covers what matters specifically for women managing weight and hormonal health, including the difference between an FDA-approved brand and an unapproved compounded product.

Semaglutide is one molecule sold under three different brands

Semaglutide is a GLP-1 receptor agonist. It is not sold to patients as "semaglutide" but under brand names, and the brand you receive is the single biggest driver of what it costs. Wegovy is the semaglutide 2.4 mg injection that the FDA label approves for chronic weight management. Ozempic is the semaglutide injection the FDA approves for type 2 diabetes. Rybelsus is the oral tablet form of semaglutide, also indicated for type 2 diabetes.

This matters for cost because insurers treat a diabetes drug and a weight-loss drug very differently, even when the active ingredient is the same. A plan that readily covers Ozempic for a diabetes diagnosis may exclude Wegovy for weight, or attach a prior-authorization requirement and a BMI threshold before it will pay a cent.

Using Ozempic for weight loss alone is off-label — the FDA approves Ozempic for type 2 diabetes, not weight management. That distinction is not just clinical; it changes whether insurance will cover the prescription and therefore what you pay at the pharmacy counter.

Why the same drug produces five completely different prices

The price you are quoted reflects your payment pathway, and there are five of them. Understanding which one you are on is the fastest way to know whether a number you have been told is realistic or a red flag.

The list price (also called wholesale acquisition cost, or WAC) is the manufacturer's published sticker price. Almost no one pays this directly, but it is the anchor everything else is discounted from. An insured copay is what your specific plan charges after it applies its formulary rules. A manufacturer savings card is a Novo Nordisk program that lowers cost for eligible commercially insured patients. Cash self-pay is the manufacturer's own direct price for people paying without insurance. And a compounded version is a non-FDA-approved copy made by a compounding pharmacy.

The gap between these pathways is enormous for the identical medication. That is why a friend's price tells you almost nothing about yours — you may simply be standing on a different rung.

The five cost pathways for semaglutide, side by side

The table below compares the five ways to pay for semaglutide and where to confirm the current number. It deliberately does not print specific dollar figures, because manufacturer prices change and the only trustworthy source is the maker's own live page.

Read this as a decision map: find the row that matches your situation, then follow it to the manufacturer resource that shows today's actual price.

Five cost pathways for semaglutide (Wegovy, Ozempic, Rybelsus). Prices change; confirm on the manufacturer's own page.
Pathway	What you actually pay	Who it typically applies to	Where to confirm the live number
List price (WAC)	The manufacturer's full published sticker price for a monthly supply	Almost no one pays this directly; it is the pre-discount anchor	NovoCare Wegovy and Ozempic coverage pages
Commercial insurance copay	A copay or coinsurance set by your plan, often after prior authorization	People with employer or marketplace plans that cover the drug for your indication	Your plan formulary plus NovoCare
Manufacturer savings card	A reduced amount for eligible commercially insured patients	Commercially insured US patients meeting Novo Nordisk's terms; generally excludes government insurance	Save on Wegovy and Save on Ozempic pages
Cash / self-pay	Novo Nordisk's direct self-pay price through its own channel	Uninsured patients, or those whose plan excludes the drug	NovoCare
Compounded semaglutide	A pharmacy-set price for a version that is not FDA-approved	Marketed by some telehealth and compounding pharmacies	Not a manufacturer product; the FDA has warned about unapproved and compounded GLP-1 products

The list price: the number almost no one actually pays

The list price is the figure most often quoted in headlines, and it is also the least useful for predicting your own cost. It is the manufacturer's published price before any insurance negotiation, rebate, savings card, or cash program is applied.

Novo Nordisk publishes cost and coverage information for both Wegovy and Ozempic through its NovoCare pages, and those are the correct place to read the current list price and understand what discounts may bring it down. Treat any list price you see as a starting ceiling, not the amount you will be charged.

If the only price a seller shows you is at or near list — with no insurance, savings program, or licensed-pharmacy structure behind it — that is a signal to slow down and verify, not to buy.

With commercial insurance: coverage depends on the diagnosis

For people with employer or marketplace (commercial) insurance, the deciding factor is whether the plan covers the specific drug for your specific indication. Many plans cover Ozempic for type 2 diabetes. Coverage for Wegovy for weight management is far less consistent — some plans cover it, many require prior authorization, and a significant number exclude weight-loss medications entirely.

When a plan does cover Wegovy for weight, it typically ties coverage to the FDA eligibility printed on the label: a BMI of 30 or higher, or a BMI of 27 or higher together with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. If your chart does not document that you meet these criteria, a prior authorization can be denied.

The practical step is to call the number on your insurance card or check your plan's formulary before your appointment, and ask two questions: is this drug on the formulary for my diagnosis, and does it require prior authorization? NovoCare's coverage pages can help you interpret the answer.

Medicare and Medicaid: a different rulebook

Government insurance follows separate rules from commercial plans, and it also changes who is eligible for savings help. Historically, coverage of medications used specifically for weight loss has been limited under Medicare, while diabetes indications are treated differently. Medicaid coverage varies by state.

This is also where manufacturer savings cards usually stop applying. Novo Nordisk's savings programs for Wegovy and Ozempic are generally restricted to commercially insured or eligible cash-paying patients and exclude people whose prescriptions are paid in whole or part by federal or state programs such as Medicare, Medicaid, or TRICARE.

If you have government coverage, the most reliable path is to confirm your plan's drug coverage directly and ask your prescriber's office about the specific indication on file, rather than assuming a savings card will apply.

Manufacturer savings cards: the biggest lever for many insured patients

For commercially insured patients, a Novo Nordisk savings card is often the single largest reduction available. Novo runs savings programs for both Wegovy and Ozempic, published on its "Save on Wegovy" and "Save on Ozempic" pages, and these are the authoritative source for current terms.

The structure typically differs depending on whether your plan already covers the drug. Patients whose plan covers the medication may pay a reduced copay; some programs also offer a separate self-pay-style offer for eligible patients whose insurance does not cover it. Eligibility, caps, and monthly limits are set by Novo and change, so the manufacturer page — not a third party — is where you confirm what you would actually pay.

Because these cards generally exclude government insurance and carry specific eligibility rules, the fastest way to get a real number for your situation is to open the manufacturer's save page for your exact product and read the current terms.

Cash and self-pay through NovoCare

If you are uninsured, or your plan flatly excludes the drug, the manufacturer's own self-pay channel is the safest cash route because it delivers the genuine FDA-approved product from a legitimate pharmacy. Novo Nordisk provides cost and access information for Wegovy and Ozempic through NovoCare.

This pathway matters because it is the honest alternative to unapproved online sellers. A cash price from the manufacturer's own program is a known quantity from a verified source; a suspiciously cheap price from an unfamiliar website is not.

As with every other pathway, the current self-pay figure lives on the manufacturer's pages and can change, so confirm it there rather than relying on a number quoted secondhand.

Compounded semaglutide: cheaper, but not an FDA-approved product

Compounded semaglutide is frequently marketed as a lower-cost option, often through telehealth platforms, and the price can look dramatically better than any branded pathway. The trade-off is significant: compounded semaglutide is not an FDA-approved product. The FDA has warned about unapproved and compounded GLP-1 products.

Availability of compounding has shifted with the branded drugs' shortage status, which is part of why offers appear and disappear. A compounded product has not gone through the FDA review that verifies the identity, strength, quality, and purity of the branded injections, and the source of the active ingredient may be unclear.

A lower price is not the same as a lower total risk. If you are weighing a compounded offer, treat the missing FDA approval as a real factor in the decision, not a technicality, and discuss it with a licensed prescriber before proceeding.

Wegovy versus Ozempic for weight loss: why the indication changes your bill

Women researching semaglutide for weight often ask whether it is cheaper to get Ozempic "for weight" instead of Wegovy. The answer is bound up in coverage. Wegovy is the semaglutide product the FDA approves for chronic weight management; using Ozempic for weight alone is off-label because Ozempic is approved for type 2 diabetes.

That off-label status has cost consequences. An insurer may decline to cover Ozempic when the documented reason is weight rather than diabetes, which can push you onto a cash or savings pathway anyway. Chasing the diabetes brand to save money can backfire if the prescription does not match a covered diagnosis.

The cleaner comparison is to price the FDA-approved weight product, Wegovy, across its own pathways — insurance, savings card, or manufacturer self-pay — rather than trying to route a weight goal through a diabetes drug.

How to lower what you pay, step by step

Start by identifying which pathway you are actually on, because that determines every other move. Confirm whether your plan covers your specific product for your specific diagnosis, and whether prior authorization is required.

If you are commercially insured, open Novo Nordisk's save page for your exact product and check current savings-card terms before filling the prescription. If you are uninsured or excluded, compare the manufacturer's NovoCare self-pay pathway rather than defaulting to an unfamiliar online seller. If a compounded option is on the table, weigh its lower price against the fact that it is not FDA-approved.

Finally, make sure your medical record documents the eligibility your insurer will check — for weight management, that means the BMI criteria on the FDA label. A prescription that clearly matches a covered indication is far more likely to be paid, which is often the difference between a manageable copay and full price.

For women managing weight and hormonal health

Weight change around perimenopause and menopause is a common reason women look into semaglutide, and cost planning here should sit inside a broader conversation with a clinician about hormonal health. Menopause hormone therapy is a separate category with its own pricing; for those costs, consult our dedicated cost pages and ACOG's patient guidance rather than assuming any figure.

One contraception note is worth flagging even though it does not apply to semaglutide directly: tirzepatide, the active ingredient in the weight drug Zepbound and the diabetes drug Mounjaro, can reduce the effectiveness of oral contraceptives, while semaglutide does not carry that warning. If you are comparing semaglutide against a tirzepatide product, this is a meaningful clinical difference to raise with your prescriber, separate from price.

Cost and clinical fit are two different questions. The cheapest pathway is not automatically the right one for your health history, and both belong in the same appointment.

Getting semaglutide legally, and what to avoid

A legitimate path to semaglutide runs through a licensed prescriber and a licensed pharmacy. That is true whether you see a clinician in person or through a telehealth service: there should be a real medical evaluation of your eligibility, a prescriber who is licensed in your state, and a pharmacy that dispenses an FDA-approved product or, if compounded, is a properly licensed compounding pharmacy whose limitations you understand.

Semaglutide is a prescription medication. Any website offering to sell it with no prescription, no medical evaluation, or shipped directly from overseas is operating outside that system, and the product may be counterfeit, mislabeled, or unsafe. A price that is far below every legitimate pathway is a warning, not a bargain.

If you want to move forward, the safe next step is to compare providers licensed in your state and confirm coverage on the manufacturer's own pages — not to hand payment details to an unverified seller.

When to see a healthcare provider

A website selling semaglutide with no prescription and no medical evaluation — semaglutide is prescription-only, and this is outside the legal system. —
Prices far below every legitimate pathway, or products shipped directly from overseas, which raises the risk of counterfeit or mislabeled medication. —
Offers of a "generic Ozempic" or "generic Wegovy" — no FDA-approved generic semaglutide exists, so such claims are a warning sign. —
Vials labeled "research only" or "not for human use," which are not a substitute for an approved prescription product. —
A compounded semaglutide offer presented as equivalent to the branded drug; it is not FDA-approved, and the FDA has warned about unapproved and compounded GLP-1 products. —
Being routed toward Ozempic for weight loss without any discussion of your diagnosis, coverage, or the off-label status, which can leave you paying full price after a denial. —

If symptoms are severe or sudden, contact your primary-care provider, OB/GYN, or a telehealth clinician for same-day evaluation. Browse providers with same-day visits.

Affiliate link Advertiser Disclosure: This site is reader-supported. We may earn an affiliate commission when you sign up for a service through links on our site. This does not influence our editorial recommendations or medical reviews. Read our full disclosure.

Frequently asked questions

Is there one standard price for semaglutide?: No. Semaglutide is sold as Wegovy (weight), Ozempic (diabetes), and Rybelsus (oral, diabetes), and what you pay depends on the brand, your diagnosis, and your payment pathway: list price, insured copay, manufacturer savings card, cash self-pay, or a non-FDA-approved compounded version. Each produces a different number for the same molecule.
Why is Wegovy sometimes not covered when Ozempic is?: Insurers treat a weight-loss drug differently from a diabetes drug even when the ingredient is identical. Wegovy is FDA-approved for chronic weight management, and many plans either require prior authorization tied to BMI criteria or exclude weight-loss medications entirely. Ozempic is approved for type 2 diabetes, which some plans cover more readily. Where to confirm: your plan formulary and NovoCare.
Do the Novo Nordisk savings cards work with Medicare or Medicaid?: Generally no. Manufacturer savings programs for Wegovy and Ozempic are typically limited to commercially insured or eligible cash-paying patients and exclude prescriptions paid by government programs such as Medicare, Medicaid, or TRICARE. Check the current terms on Novo Nordisk's Save on Wegovy and Save on Ozempic pages.
Is compounded semaglutide a safe way to pay less?: Compounded semaglutide is often cheaper but is not an FDA-approved product, and the FDA has warned about unapproved and compounded GLP-1 products. It has not gone through the review that verifies identity, strength, quality, and purity. A lower price does not remove that risk, so discuss it with a licensed prescriber before choosing this route.
Where can I find the actual current price?: On the manufacturer's own pages. Novo Nordisk publishes cost, coverage, and savings information for Wegovy and Ozempic through its NovoCare and savings pages. These figures change, so treat any price quoted elsewhere as approximate and confirm it at the source.
Can I use Ozempic for weight loss to save money?: Using Ozempic for weight alone is off-label, since Ozempic is FDA-approved for type 2 diabetes, not weight management. Insurers may decline coverage when the documented reason is weight, which can push you to a cash pathway anyway. The FDA-approved weight product is Wegovy, and pricing it across its own pathways is usually the cleaner comparison.
What BMI do I need for insurance to cover semaglutide for weight?: Insurers that cover Wegovy for weight typically follow the FDA eligibility on the label: a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. If your record does not document this, a prior authorization can be denied.
Does semaglutide affect birth control like some other weight drugs?: Semaglutide does not carry the oral-contraceptive warning that tirzepatide does. Tirzepatide, the ingredient in Zepbound and Mounjaro, can reduce the effectiveness of oral contraceptives. If you are comparing semaglutide against a tirzepatide product, raise this difference with your prescriber alongside any cost comparison.

Primary sources

ClearHormones publishes editorial health information for education only — not medical advice.